labor

SSR126768A is a novel and selective, orally active and potent oxytocin (OT) receptor antagonist with inhibitory effects on uterine contractions for the prevention of preterm labor.

Valethamate bromide (Resitan) is an anticholinergic agent that has antispasmodic effects and inhibits glandular secretion.

Camylofin HCl is an antispasmodic used in labor treatment and is also used to deliver drug therapy for ulcerative colinitis.

Dinoprost (Prostaglandin F2a) is a naturally occurring prostaglandin. It is used in medicine to induce labor and as an abortifacient.

Phencarbamide napadisilate is an antispasmodic and anticholinergic compound used during labor.

Phencarbamide is an antispasmodic and anticholinergic compound, frequently utilized during labor. The compound acts directly on smooth muscle.

Delprostenate is similar to PGF(2alpha), a naturally occurring prostaglandin used in medical labor induction and abortion drugs.

15(S)-15-methyl Prostaglandin F2α (15(S)-15-methyl PGF2α) has been shown to have potent uterine stimulant and abortifacient properties when administered intramuscularly to induce labor. 15(S)-15-methyl PGF2α isopropyl ester is a lipophilic analog of 15(S)-15-methyl PGF2α methyl ester, which may be hydrolyzed in vivo to the fully active free acid.

5β-Dihydroprogesterone (5β-DHP) is a progesterone receptor agonist and metabolite of progesterone .1,2It is formed from progesterone by 5β-reductase.25β-DHP inhibits spontaneous contractions in isolated rat uterus when used at a concentration of 10 μg/ml, an effect that can be blocked by the progesterone receptor antagonist RU486 but not the GABAAreceptor antagonist picrotoxin .1It is a negative modulator of homooligomeric Ρ1 subunit-containing GABAAreceptors, inhibiting GABA-induced currents inX. laevisoocytes expressing these receptors (IC50= 5.02 μM).3Plasma levels of 5β-DHP decrease at the onset of spontaneous human labor.4

Dinoprost tromethamine salt (PGF2α THAM) is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.

Atosiban (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Oxytocin (Syntocinon) is a mammalian neuropituitary hormone, a pleiotropic hypothalamic peptide and ligand for the oxytocin receptor, which contributes to labor, lactation, and pro-social behavior. Oxytocin has the ability to stimulate mammary secretion of breast milk, promote contraction of uterine smooth muscle during labor, and facilitate mothering.

Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Ritodrine (DU21220) is a β-adrenergic agonist and uterine relaxant useful in research on arresting premature labor[1][2].

Isoxsuprine Free Base is a beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.

Ebopiprant, also known as OBE-022, is an Oral and Selective Prostaglandin F 2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. OBE022 exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects seen with indomethacin.

Erlosiban, also known as OBE001, is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate in assisted reproductive technology (ART).

11,12-DiHETrE, a Cytochrome P450 (P450) eicosanoid and endogenous metabolite, holds potential as a single biomarker for differentiating nonalcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH) [1] [2]. Additionally, it is utilized in preterm labor research.

Demoxytocin, an analog of oxytocin and a heterodetic cyclic peptide, enhances cell membrane permeability to elevate calcium ion levels in smooth muscle cells, thereby augmenting contraction, including the smooth muscles of the uterus. This compound mirrors oxytocin's function and is utilized in studies focusing on labor induction following premature rupture [1].

PDC31 (THG113.31; ILGHXDYK) is a D-amino acid-based oligopeptide that acts as an allosteric and non-competitive inhibitor of the FP Prostaglandin Receptor, used primarily as a smooth muscle contractile agent. It effectively reduces the strength and duration of uterine contractions in vivo, offering potential for preterm labor and primary dysmenorrhea (PD) research. Additionally, PDC31 enhances the Ca2+-dependent large-conductance K+-channel in human myometrial cells [1] [2].

RYTVELA TFA (H-Arg-Tyr-Thr-Val-Glu-Leu-Ala-OH) is a non-competitive metabotropic interleukin-1 receptor inhibitor with anti-inflammatory activity that inhibits upregulation of inflammation and uterine activation, and may be used for the prevention of preterm labor and for fetal protection.

13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) serves as the predominant metabolite of PGE2 in plasma, created through a 15-keto PGE2 intermediate by the action of 15-oxo-PG Δ13 reductase. Unlike its precursor PGE2, this compound exhibits poor binding affinity towards EP2 and EP4 PGE2 receptors (Ki values of 12 and 57 µM, respectively) in CHO cells and fails to stimulate adenylate cyclase activity therein (EC50s >18 and >38 µM, respectively). Concentrations of 13,14-dihydro-15-keto PGE2 are notably higher in the plasma of pregnant women during their third trimester and at labor and delivery stages, whereas its levels are found to be reduced in the tumor tissues of patients with non-small cell lung cancer (NSCLC) compared to adjacent healthy tissue.